Neurogene Inc. Line of Credit Facility, Increase, Accrued Interest
Neurogene Inc. (NGNE) reported Line of Credit Facility, Increase, Accrued Interest of $9.84 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-16.
Discontinued › Notes
us-gaap:LineOfCreditFacilityIncreaseAccruedInterest · last filed 2015-03-16
- Neurogene Inc. line of credit facility, increase, accrued interest for the quarter ending 2014-12-31 was $0.00.
- Neurogene Inc. line of credit facility, increase, accrued interest for the quarter ending 2014-09-30 was $0.00.
- Neurogene Inc. line of credit facility, increase, accrued interest for the quarter ending 2014-06-30 was $0.00.
- Neurogene Inc. line of credit facility, increase, accrued interest for the quarter ending 2014-03-31 was $9.84K.
- Neurogene Inc. line of credit facility, increase, accrued interest for fiscal 2014 was $9.84K.
| Period end | Line of Credit Facility, Increase, Accrued Interest 3 month | Line of Credit Facility, Increase, Accrued Interest 6 month | Line of Credit Facility, Increase, Accrued Interest 9 month | Line of Credit Facility, Increase, Accrued Interest 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $0.00 derived: sum of 2 quarters · filed 2015-03-16 | $0.00 derived: sum of 3 quarters · filed 2015-03-16 | $9.84K 10-K · filed 2015-03-16 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $0.00 derived: sum of 2 quarters · filed 2014-11-04 | $9.84K 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $9.84K 10-Q · filed 2014-08-11 | ||
| 2014-03-31 | $9.84K 10-Q · filed 2014-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |